Predict your next investment

Corporate Venture
illuminaventures.com

See what CB Insights has to offer

Investments

51

Portfolio Exits

5

Funds

2

Partners & Customers

1

Service Providers

1

About Illumina Ventures

Illumina Ventures pursues investments in early stage companies that are pioneering new applications of nucleic acid sequencing, developing products that will expand the genomics ecosystem, and utilizing genomics to improve human health.

Illumina Ventures Headquarter Location

499 Illinois Street Suite 210

San Francisco, California, 94158,

United States

858-210-1824

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Illumina Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Illumina Ventures in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Illumina Ventures News

04:00 EDT Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

Jun 28, 2022

News provided by Share this article Share this article Investment from LifeArc, Illumina, and Illumina Ventures will fund genomics startups for Illumina Accelerator Cambridge graduates SAN DIEGO, June 28, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health. Illumina Accelerator, located in both San Francisco and Cambridge, is a company creation engine that partners with entrepreneurs to create genomics startups and advance innovative applications. Illumina joins a select group of US and European investors in the life sciences fund, including cornerstone investor LifeArc. Illumina announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health. Illumina Accelerator is a company creation engine that partners with entrepreneurs to create genomics startups and advance innovative applications. Since opening in July 2020, Illumina Accelerator Cambridge has launched 13 startups focused on harnessing genomics applications to improve human health, including novel therapeutics, diagnostics, synthetic biology, research tools, and agriculture. In addition, approximately 54% of Illumina Accelerator Cambridge startups have been founded by women—by comparison, in 2020, only 20% of all new startups over the previous year had female founders, according to CrunchBase. "Time Boost Capital Fund will further propel our Illumina Accelerator Cambridge startups and advance our mission to improve human health by unlocking the power of the genome," said Amanda Cashin, PhD, cofounder and global head of Illumina for Startups. "Cambridge is a leading global hub for life science innovation and entrepreneurship, and this dedicated venture fund will attract the most exceptional entrepreneurs from across the globe." Time Boost Capital's £30 million in capital commitments from select US and European investors include a £10 million commitment from LifeArc, a leading UK independent medical research charity, and investment from Illumina Ventures, an independent fund investing in genomics and precision health. Time Boost Capital will provide pound-for-pound match funding to every Illumina Accelerator Cambridge graduate that secures between £500,000 and £4 million in new capital from qualified investors within 18 months of acceptance. The fund is advised by Time Partners, a private markets investment adviser focused on long-term investment solutions. "We are proud to partner with Illumina, a global leader in next-generation sequencing technologies," said Mark Florman, CEO of Time Partners Limited. "Illumina is making a significant commitment to supporting new growth in the field through Illumina Accelerator. As an investment advisor to Time Boost Capital, we have the unique opportunity to back some of the most promising new genomics businesses in the world." During two 6-month funding cycles each year, Illumina Accelerator provides selected startups with access to seed investment, Illumina sequencing systems and reagents, business guidance, genomics expertise, and fully operational lab space adjacent to Illumina's campuses in Cambridge and the San Francisco Bay Area. "Illumina Accelerator's track record in building breakthrough genomics startups is unparalleled," said Alex Aravanis, MD, PhD, chief technology officer of Illumina. "The partnership with Time Partners to provide match funding to our graduates of Illumina Accelerator Cambridge will further advance innovative genomic discoveries that will benefit people around the world." Illumina Accelerator Cambridge alumni include Alchemab Therapeutics Ltd. , a therapeutics company pioneering the next generation of antibody drugs, which successfully raised £60 million in series A funding upon graduation. Another alumni is recent graduate Broken String Biosciences Ltd ., a sequencing tools company focused on assessing the stability of the genome, which secured £3 million in seed funding. Illumina Accelerator is accepting applications for the next global funding cycle, which are due by October 1, 2022. Through a single, global application process, Illumina Accelerator will select up to five companies in each location. To learn more and apply, please visit illumina.com/science/accelerator.html . About Illumina for Startups Illumina for Startups is focused solely on creating an innovation ecosystem for the genomics industry by partnering with leading venture capital investors and entrepreneurs to create, launch, and grow genomics startups. Illumina for Startups initiatives include Illumina Accelerator, founded in 2014, and Sequoia Capital China Intelligent Healthcare Genomics Incubator, powered by Illumina, founded in 2021. Illumina Accelerator is a company creation engine colocated with Illumina research and development sites in the San Francisco Bay Area and Cambridge, England. Since its inception, Illumina Accelerator has invested in 68 genomics startups across the globe, which have collectively raised over $1 billion in venture capital funding. Approximately 93% of Illumina Accelerator investments have gone on to raise additional capital from leading investors. For more information, visit illumina.com/science/accelerator.html . About Time Partners Time Partners provides independent tailored solutions to major family businesses and institutions across the world with a particular focus on building and creating sustainable investing strategies. We provide specialist advice to investors seeking to build long-term private markets investment programmes and strategic advice to institutions seeking solutions in corporate finance, restructuring, and the design of investment vehicles with a broader purpose. Time Partners was formed in 2013 as a private markets investment adviser combining best advice, creative solutions and a client first philosophy. For more information, visit our website . About LifeArc LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and academic scientists. Find out more about our work on  www.lifearc.org  or follow us on  LinkedIn  or  Twitter . About Illumina Ventures Illumina Ventures is an independently managed, health-care-focused venture firm in a strategic partnership with Illumina. As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, and personal wellness. For more information, visit  illuminaventures.com . About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit  illumina.com  and connect with us on  Twitter ,  Facebook ,  LinkedIn ,  Instagram , and  YouTube . Investors:

Illumina Ventures Investments

51 Investments

Illumina Ventures has made 51 investments. Their latest investment was in Baebies as part of their Series C on May 5, 2022.

CBI Logo

Illumina Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/3/2022

Series C

Baebies

$37.57M

No

1

3/8/2022

Series B

Sherlock Biosciences

$80M

Yes

18

2/15/2022

Series D

Kallyope

$236M

No

20

11/23/2021

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

11/9/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/3/2022

3/8/2022

2/15/2022

11/23/2021

11/9/2021

Round

Series C

Series B

Series D

Convertible Note

Series B

Company

Baebies

Sherlock Biosciences

Kallyope

Subscribe to see more

Subscribe to see more

Amount

$37.57M

$80M

$236M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

18

20

10

10

Illumina Ventures Portfolio Exits

5 Portfolio Exits

Illumina Ventures has 5 portfolio exits. Their latest portfolio exit was Cernostics on October 19, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/19/2021

Acquired

$99M

3

6/17/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

10/30/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/29/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/19/2021

6/17/2021

10/30/2020

10/31/2018

5/29/2018

Exit

Acquired

Reverse Merger

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Illumina Ventures Fund History

2 Fund Histories

Illumina Ventures has 2 funds, including Illumina Innovation Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/20/2021

Illumina Innovation Fund II

$325M

3

10/16/2017

Illumina Innovation Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

9/20/2021

10/16/2017

Fund

Illumina Innovation Fund II

Illumina Innovation Fund I

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$325M

$99M

Sources

3

10

Illumina Ventures Partners & Customers

1 Partners and customers

Illumina Ventures has 1 strategic partners and customers. Illumina Ventures recently partnered with AltaReturn on April 4, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

4/24/2017

Vendor

United States

AltaReturn selected by Illumina Ventures - Allvue Systems

About Illumina Ventures : Illumina Ventures is an independently-managed venture fund with A strategic partnership with Illumina Ventures .

1

Date

4/24/2017

Type

Vendor

Business Partner

Country

United States

News Snippet

AltaReturn selected by Illumina Ventures - Allvue Systems

About Illumina Ventures : Illumina Ventures is an independently-managed venture fund with A strategic partnership with Illumina Ventures .

Sources

1

Illumina Ventures Service Providers

1 Service Provider

Illumina Ventures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Illumina Ventures Team

2 Team Members

Illumina Ventures has 2 team members, including current Founding Partner, Nicholas Naclerio.

Name

Work History

Title

Status

Nicholas Naclerio

Illumina, Zyomyx, Motorola, Defense Advanced Research Projects Agency, and U.S. Air Force

Founding Partner

Current

Patrick Gordan

Chief Operating Officer

Former

Name

Nicholas Naclerio

Patrick Gordan

Work History

Illumina, Zyomyx, Motorola, Defense Advanced Research Projects Agency, and U.S. Air Force

Title

Founding Partner

Chief Operating Officer

Status

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.